
Efficacy and Durability of Intravenous Ertapenem Therapy for Recalcitrant HS
Summary Verified By: Steven Cohen, MD, MPH | Weill Cornell Dermatology Center for Hidradenitis Suppurativa
February 13, 2024
This plain-language research summary was generated by AI, courtesy of HS Simplified.
Efficacy and Durability of Intravenous Ertapenem Therapy for Recalcitrant HS
In a retrospective analysis from 2018 to 2022, published in 2024, researchers explored the potential of intravenous ertapenem, a powerful antibiotic, in treating hidradenitis suppurativa (HS). HS is a chronic, debilitating skin condition marked by painful pustules and nodules. The study found that administering ertapenem over 12-16 weeks significantly improved clinical and inflammatory markers, leading to high patient satisfaction, but also highlighted the need for careful management to prevent antimicrobial resistance. More recent studies by this group have resulted in a benchmark treatment interval of 16 weeks or more. Since the original publication, there has only been one case of antibiotic resistance.
A New Way to Treat Tough Skin Disease: Intravenous Ertapenem for Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a painful, long-lasting skin problem. People with HS get swollen, sore bumps and tunnels under their skin, usually in places like their armpits, breasts (mostly in women), abdominal fold (in heavier individuals), groin, upper thighs, and buttocks. These bumps can burst, leak pus, and leave scars. HS can make people feel sad, embarrassed, and hopeless because it’s hard to treat and can hurt a lot.
Doctors usually try different treatments for HS, like creams, pills, and even surgery. Antibiotics—medicines that kill bacteria—are often used, but sometimes they don’t work well if the HS is really bad. In this study, Nosrati and other researchers wanted to know if a special antibiotic called ertapenem could help people with severe, stubborn HS. Ertapenem is given through a vein (intravenous or IV), not by mouth.
How Was the Study Done?
The scientists looked at the medical records of 98 people with HS who got ertapenem treatment at home for about 13 weeks. The medicine was given through a special tube called a peripheral intravenous central catheter (PICC) line. Most patients kept taking their other HS medicines (including hormone therapies and anti-inflammatory treatments) during this time, except for regular antibiotics by mouth.
The researchers checked how bad the HS was before, during, and after treatment. They used special scores to measure pain and skin severity. They also checked blood tests for signs of inflammation (like sedimentation rate, C-reactive protein and interleukin-6), and asked patients how happy they were with the treatment in a phone survey.
What Did the Scientists Find?
After about 13-weeks of IV ertapenem, most patients felt much better. Their skin bumps were less severe, and their pain scores dropped by more than half. Inflammation in the blood also got lower. In the follow-up survey, over 80% of people said they were satisfied with the treatment, and almost all would recommend it to others with HS.
Side effects were usually mild. Some people had diarrhea, nausea, or headaches, and a few had problems with the PICC line, but nobody had to stop treatment because of side effects.
Why Is This Important?
This study shows that IV ertapenem can help people with severe HS who haven’t gotten better with other treatments. It can reduce pain, swelling, and the number of skin bumps, and most people are happy with the results. The treatment is safe for most patients and can even help prepare some people for surgery if they need it.
Limitations of the Study
There are some things to keep in mind. This study did not have a control group (a group of people who did not get ertapenem), so it’s hard to be certain that all the improvements were because of the drug. It was also only done at one hospital, and people who didn’t have a follow-up visit after treatment were not counted—maybe because the treatment didn’t work for them. Also, giving antibiotics for a long time (over 3 months) could cause antibiotic resistance, which means bacteria might stop responding to the medicine in the future. More research is needed to know the best length of treatment and how to avoid this problem.
What Does This Mean for Patients?
If you or someone you know has severe HS that isn’t getting better with usual treatments, IV ertapenem for about 3-4 months could be an option to try. It helps most people feel better and has a good safety record, but it should be done under close doctor supervision. Scientists are still working to find out the best way to use this treatment and keep it working for the future.
Author(s)
Avigdor Nosrati, Peter Y. Ch’en, McCall E. Torpey, Neda Shokrian, Gretchen Ball, Gabrielle Benesh, Tyler M. Andriano, Tian Ran Zhu, Haley D. Heibel, H. Dean Hosgood, Kristina L. Campton, Steven R. Cohen
